Login to Your Account



ImClone Reports Erbitux Sales Of $71.4M, Plans sBLA Filing

By Kim Coghill


Thursday, July 22, 2004
ImClone Systems Inc.'s stock fell 18.9 percent Wednesday even though the firm turned a profit on Erbitux sales and said it intends to request FDA approval of the drug in head and neck cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription